With exome sequences for tens of thousands of Finns, researchers identified deleterious variants linked to dozens of clinically relevant quantitative traits.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.
The Genes for Good Project has engaged 80,000 Facebook users via its online application and genotyped 27,000 people to date.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
The University of Michigan researchers aim to commercialize the Hydro-Seq microfluidic platform, which isolates and prepares single circulating tumor cells for RNA sequencing.
With exome sequences from tens of thousands of T2D cases or controls from five ancestral groups, researchers identified genes that are frequently impacted by rare T2D-linked variants.
The new technique, enabled by enzymatic library preparation and a tight bioinformatics pipeline, could have applications in liquid biopsy.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
Some 43 percent of new mothers and 23 percent of new fathers leave full-time employment in STEM in the years after having a child, Science Careers says.
Researchers used exome capture RNA sequencing to come up with a collection of circRNAs in dozens of cancer types, including proposed prostate cancer markers.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.